Go to the briefing

An offer is the start of a question

Does the claim fit your problem?

Will the proposed peptide help your injury heal? Peptides, including insulin, contain tiny chemical parts that form short chains. You might picture beads threaded together. The FDA information below is about ingredients and possible harm. It does not show that BPC-157 or TB-500 can heal your injury. Ask for studies of the exact medicine in people with your problem.

Look closer · a learning step

Weigh the evidence behind the offer

The Food and Drug Administration reviews drugs at the federal level; FDA is its short name.

For BPC-157, FDA reported too little human safety information to judge harm in the records checked in September 2026.

Note A

This means FDA did not have enough information about possible harm. It does not answer whether the drug helps an injury heal.

Ask the clinician to separate what the product is from what evidence says it may achieve.

What would count as a useful answer?

  • Was the exact substance and form studied?
  • Did the study involve people with the problem being discussed?
  • What was it compared with?
  • What counted as an improvement?
  • What unwanted effects were recorded?

Ask for the study name or source. Take time to read the answer. If the explanation stays vague, ask what it leaves unknown.

How much weight can an advert carry?

The Federal Trade Commission says health advertising claims need scientific evidence behind them, in guidance checked in September 2026.

Note B

That rule does not tell you whether an advertiser has actually provided the evidence.

Bring the claim to the visit. Ask for its limits as well as its best case.

See what approval means

Page notes

  1. FDA discussion of peptide information gaps

    Not knowing enough about harm does not show that a medicine helps an injury heal.

    Back to the briefing
  2. Federal Trade Commission on health claims

    An advert is not reviewed by a government agency before it goes public.

    Back to the briefing